LMAT

LeMaitre Vascular Inc. (LMAT) | Rumor.io

LeMaitre Vascular

LMAT

Attention (50-day avg)0%

Attention rank (50-day avg)#4,125

Bullish sentiment (50-day avg)63%

Price to earnings ratio28.6

Market capitalization1.9B

Earnings per share2.86

Dividend yield (TTM)1.21%

Revenue (annual)249.6M

Net income (annual)57.7M

Social

What share of all stock conversation is about LMAT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 5

LeMaitre Vascular, Inc. ($LMAT) has seen its stock price drop ~19.4% after missing Q2 earnings expectations and trimming its full-year sales growth outlook.
The company's operating margin hit 29% as capital spending jumped 87% in the three months ended June, but this expansion was not free.
LeMaitre is facing heightened regulatory and product-quality risk, with approvals potentially being withdrawn, and the company is also facing new observations at the Artegraft facility.

Generated by AI

Sentiment

Of the messages about LMAT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +42.86	99.56% +0.87
Bearish	—	—	0% -42.86	0.44% -0.87

Bullish· Jul 28

LeMaitre Vascular, Inc. ($LMAT) has delivered strong Q2 results and guidance, propelling shares ahead 18%.
Benchmark Co. has upgraded LeMaitre Vascular to a Buy rating, with shares ahead 22% following the announcement.
LeMaitre Vascular's EPS growth estimate in 3 years is expected to be 64.6%, a significant increase that could drive further growth in the company.

Bearish· Oct 27

$LMAT has been downgraded to Equal Weight from Overweight by First Analysis, with a target price of $34.
The Benchmark Company has cut its rating on $LMAT to Hold from Buy, citing a lower price target of $29.00.
LeMaitre Vascular, Inc.'s stock price has fallen 16% after being downgraded by Benchmark Co. to Hold and by First Analysis to Equal Weight.

Generated by AI

Topics

Of the messages about LMAT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	0.94%
Technical Analysis	—	—	—	0.15%
Earnings	—	—	—	0.02%
Analysts	—	—	—	49.58%
Controversies	—	—	—	0%
Macro	—	—	—	49.31%

Earnings· Apr 25

LeMaitre Vascular, Inc. ($LMAT) reported FQ1 earnings of 19c EPS and $25.99M Revs.
The company missed EPS estimates by $0.02 and revenue estimates, but guided Q2 EPS above consensus and revenue below consensus.
$LMAT reported Q1 2018 sales of $26.0mm, up 8% from the prior year, and EPS of $0.19, up 17% from the prior year.

Analysts· Oct 8

Barrington Research upgraded LeMaitre Vascular's rating to Outperform from Market Perform with a $34 target price.
Several analysts, including Barrington Research and Roth Capital, have upgraded LeMaitre Vascular's stock rating in recent days.
The upgrades were driven by a combination of factors, including a recent Barrington Research upgrade to Outperform with a $34 target price.

Announcements· Jun 20

LeMaitre Vascular, Inc. (LMAT) has been mentioned in the context of advancements at ASCO 2024, highlighting the integration of AI and mRNA biomarkers by Mainz Biomed (MYNZ) for colorectal cancer detection.
The announcement reports a 92% sensitivity rate for colorectal cancer detection by Mainz Biomed's technology, which combines AI and mRNA biomarkers.
LeMaitre Vascular, Inc. (LMAT) has been indirectly referenced as a related company in the medical innovation space, alongside Mainz Biomed (MYNZ) and LOBO.

Generated by AI

Community

Of the messages about LMAT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	4.6%
Newcomers	—	—	100%	95.4%

Regulars· Jul 29

LeMaitre Vascular's CEO George W. LeMaitre has been filing SEC forms 4, indicating changes in his stock holdings, with the most recent filing showing a decrease in his common stock holdings.
Insider Trent G. Kamke has been selling shares of LeMaitre Vascular, with the most recent sale involving 13,804 shares.
LeMaitre Vascular has announced that it will present at upcoming investor conferences, and has also declared a quarterly dividend of $0.10 per share.

Newcomers· Aug 5

Newcomers are focused on the recent decline in LMAT stock price, with a drop of -24.5% and a price of $79.84.
There are concerns about LMAT's growth prospects, with a short report highlighting reliance on price-driven growth and decelerating organic growth, and Q2 results risk underperformance.
The company is facing heightened regulatory and product-quality risk, including FDA warning letters, product liability suits, and potential recalls, which could impact its financials and reputation.

Generated by AI

LeMaitre Vascular (LMAT) is drawing fresh attention after its shares closed at US$80.58, with recent returns showing modest gains over the past month and a decline over the past 3 months. Viewed over a longer stretch, LeMaitre Vascular’s 1 year total shareholder return is down 7.29%, even as the 3 year total shareholder return of 54.81% and 5 year total shareholder return of 56.88% point to earlier strength that has cooled with the recent 90 day share price pullback of 14.21% from current...

5d agoYahoo Finance

LeMaitre Vascular (LMAT) Stock Looks Fully Priced On Its 57% Five Year Run

LeMaitre Vascular has delivered a 56.9% share price gain over the past five years, yet its recent flat patch raises a simple question for you as an investor. Are the cash flows from this medical device business strong and reliable enough to support where the stock trades today? That 56.9% move over five years puts real weight on whether LeMaitre Vascular's cash generation can support the value the market now assigns to the business. The company focuses on vascular devices that can support...

6d agoYahoo Finance

LeMaitre Vascular stock hits 52-week low at 78.22 USD

8d agoInvesting.com

Speculative Rally Weighed on LeMaitre Vascular (LMAT)

Riverwater Partners, an investment management company, released its ‘Small Cap Strategy’ Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined […]

28d agoYahoo Finance

LeMaitre to Participate at Upcoming Investor Conferences in September

BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences. Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026, in BostonDorian LeBlanc, CFO, will participate in a Fireside Chat at 8:45 AM ET Morgan Stanley 24th Annual Global Healthcare Conference Wednesday, September 16, 2026, in New York CityDorian LeBlanc, CFO, will participate in a Fireside Chat at 12:

1mo agoYahoo Finance

Lemaitre Vascular stock hits 52-week low at 78.64 USD

1mo agoInvesting.com

Also Discussed

Investors talking about LMAT also mention

#	Name	Attention
1	Supernus Pharmaceuticals, Inc.SUPN	0%new
2	Klaviyo Inc.KVYO	0%0
3	LivaNova PLCLIVN	0%0
4	ANGI Homeservices IncANGI	0%0
5	Extreme Networks Inc.EXTR	0%new
6	Global Business Travel Group, Inc.GBTG	0%new
7	SSR Mining Inc.SSRM	0%new
8	Littelfuse Inc.LFUS	0%new
9	New York Times Co.NYT	0%-0.01
10	Match Group Inc.MTCH	0%new

LeMaitre Vascular Inc.

Healthcare
Medical Instruments & Supplies

LeMaitre Vascular Inc. is a medical device company focused on products and services used in vascular surgery and the treatment of peripheral vascular disease. The company develops, manufactures, and markets a specialized portfolio that includes biologic patches, vascular grafts, catheters, carotid shunts, valvulotomes, radiopaque marking tape, and other disposable and implantable tools used to repair blood vessels and support bypass, access, and clot-removal procedures. LeMaitre Vascular also provides human tissue cryopreservation services for implantation, adding a complementary service component to its device business. Its offerings are used by vascular surgeons and related specialists in hospitals and surgical settings, giving the company a focused role in a niche segment of the broader medical technology market.

Website

Location

63 Second Avenue

Burlington, MA, 01803

United States

Social

What share of all stock conversation is about LMAT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 5

LeMaitre Vascular, Inc. ($LMAT) has seen its stock price drop ~19.4% after missing Q2 earnings expectations and trimming its full-year sales growth outlook.
The company's operating margin hit 29% as capital spending jumped 87% in the three months ended June, but this expansion was not free.
LeMaitre is facing heightened regulatory and product-quality risk, with approvals potentially being withdrawn, and the company is also facing new observations at the Artegraft facility.

Generated by AI

Sentiment

Of the messages about LMAT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +42.86	99.56% +0.87
Bearish	—	—	0% -42.86	0.44% -0.87

Bullish· Jul 28

LeMaitre Vascular, Inc. ($LMAT) has delivered strong Q2 results and guidance, propelling shares ahead 18%.
Benchmark Co. has upgraded LeMaitre Vascular to a Buy rating, with shares ahead 22% following the announcement.
LeMaitre Vascular's EPS growth estimate in 3 years is expected to be 64.6%, a significant increase that could drive further growth in the company.

Bearish· Oct 27

$LMAT has been downgraded to Equal Weight from Overweight by First Analysis, with a target price of $34.
The Benchmark Company has cut its rating on $LMAT to Hold from Buy, citing a lower price target of $29.00.
LeMaitre Vascular, Inc.'s stock price has fallen 16% after being downgraded by Benchmark Co. to Hold and by First Analysis to Equal Weight.

Generated by AI

Topics

Of the messages about LMAT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	0.94%
Technical Analysis	—	—	—	0.15%
Earnings	—	—	—	0.02%
Analysts	—	—	—	49.58%
Controversies	—	—	—	0%
Macro	—	—	—	49.31%

Earnings· Apr 25

LeMaitre Vascular, Inc. ($LMAT) reported FQ1 earnings of 19c EPS and $25.99M Revs.
The company missed EPS estimates by $0.02 and revenue estimates, but guided Q2 EPS above consensus and revenue below consensus.
$LMAT reported Q1 2018 sales of $26.0mm, up 8% from the prior year, and EPS of $0.19, up 17% from the prior year.

Analysts· Oct 8

Barrington Research upgraded LeMaitre Vascular's rating to Outperform from Market Perform with a $34 target price.
Several analysts, including Barrington Research and Roth Capital, have upgraded LeMaitre Vascular's stock rating in recent days.
The upgrades were driven by a combination of factors, including a recent Barrington Research upgrade to Outperform with a $34 target price.

Announcements· Jun 20

LeMaitre Vascular, Inc. (LMAT) has been mentioned in the context of advancements at ASCO 2024, highlighting the integration of AI and mRNA biomarkers by Mainz Biomed (MYNZ) for colorectal cancer detection.
The announcement reports a 92% sensitivity rate for colorectal cancer detection by Mainz Biomed's technology, which combines AI and mRNA biomarkers.
LeMaitre Vascular, Inc. (LMAT) has been indirectly referenced as a related company in the medical innovation space, alongside Mainz Biomed (MYNZ) and LOBO.

Generated by AI

Community

Of the messages about LMAT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	4.6%
Newcomers	—	—	100%	95.4%

Regulars· Jul 29

LeMaitre Vascular's CEO George W. LeMaitre has been filing SEC forms 4, indicating changes in his stock holdings, with the most recent filing showing a decrease in his common stock holdings.
Insider Trent G. Kamke has been selling shares of LeMaitre Vascular, with the most recent sale involving 13,804 shares.
LeMaitre Vascular has announced that it will present at upcoming investor conferences, and has also declared a quarterly dividend of $0.10 per share.

Newcomers· Aug 5

Newcomers are focused on the recent decline in LMAT stock price, with a drop of -24.5% and a price of $79.84.
There are concerns about LMAT's growth prospects, with a short report highlighting reliance on price-driven growth and decelerating organic growth, and Q2 results risk underperformance.
The company is facing heightened regulatory and product-quality risk, including FDA warning letters, product liability suits, and potential recalls, which could impact its financials and reputation.

Generated by AI

LeMaitre Vascular

Social

Aug 5

Bullish· Jul 28

Bearish· Oct 27

Earnings· Apr 25

Analysts· Oct 8

Announcements· Jun 20

Regulars· Jul 29

Newcomers· Aug 5

Is LeMaitre Vascular (LMAT) A Bargain Following Its 90 Day Pullback?

LeMaitre Vascular (LMAT) Stock Looks Fully Priced On Its 57% Five Year Run

LeMaitre Vascular stock hits 52-week low at 78.22 USD

Speculative Rally Weighed on LeMaitre Vascular (LMAT)

LeMaitre to Participate at Upcoming Investor Conferences in September

Lemaitre Vascular stock hits 52-week low at 78.64 USD

Also Discussed

LeMaitre Vascular Inc.

Company Information

Location

Social

Aug 5

Bullish· Jul 28

Bearish· Oct 27

Earnings· Apr 25

Analysts· Oct 8

Announcements· Jun 20

Regulars· Jul 29

Newcomers· Aug 5

Is LeMaitre Vascular (LMAT) A Bargain Following Its 90 Day Pullback?

LeMaitre Vascular (LMAT) Stock Looks Fully Priced On Its 57% Five Year Run

LeMaitre Vascular stock hits 52-week low at 78.22 USD

Speculative Rally Weighed on LeMaitre Vascular (LMAT)

LeMaitre to Participate at Upcoming Investor Conferences in September

Lemaitre Vascular stock hits 52-week low at 78.64 USD

Also Discussed